NLRP3 and triple-A syndrome: Enhancing the autophagy/mitophagy pathway pharmacologically, either with MN58b or Metformin, effectively prevented the development of LCWE-induced cardiovascular lesions, such as heart inflammation and AAA, by downregulating the NLRP3/IL-1β pathway.